ArticleInternational ophthalmology2025
Glutathione peroxidase 3 antagonizes oxidative stress and inflammation in diabetic retinopathy via NrF2/NF-κB pathway.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endothelial activation in thromboangiitis obliterans: mechanisms and therapeutic horizons.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHyperglycemia-oxidative stress (OS)-inflammation-apoptosis cascade reaction is an important pathogenesis of diabetes retinopathy (DR). However, the function of glutathione peroxidase 3 (GPX3), an important antioxidant molecule, in the pathogenesis of DR remains unclear. This study aims to explore the function and mechanism of GPX3 mediated OS in the occurrence and development of DR.
methodsHuman retinal capillary endothelial cells (HRCECs) were cultured in vitro to construct a high glucose environment, GPX3 deficiency, and GPX3 overexpression HRCEC cell model. Cell proliferation activity, OS level, inflammation, apoptosis, and NrF2/NF-κB pathway expression were detected by CCK-8 assay, qRT-PCR, Western blot, and flow cytometry.
resultsThe high glucose treatment resulted in a time and dose dependent decrease in the proliferation activity and GPX3 expression level of HRCECs, and promoted the occurrence of cell OS, inflammation, and apoptosis. At the same time, it inhibited the expression of nuclear factor erythroid 2-related factor 2 (NrF2) and up-regulated the expression of nuclear factor kappa B (NF-κB); The down-regulation of GPX3 expression exacerbated the effects of high glucose environment on the OS, inflammation, apoptosis, and NrF2/NF-κB pathway of HRCECs, while overexpression of GPX3 can partially antagonize the effects of high glucose environment on the OS, inflammation, apoptosis, and NrF2/NF-κB pathway of HRCECs.
conclusionsTargeted regulation of GPX3, which is down-regulated and inactivated in DR, is expected to mediate the occurrence and development of OS, inflammation, and cell apoptosis in DR through the NrF2/NF-κB pathway.
Indexed as
Identifiers
40478328What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.